New drug duo tested for Tough-to-Treat esophageal cancer
NCT ID NCT04921904
Summary
This early-stage study is testing the safety and effectiveness of combining two drugs, abemaciclib and ramucirumab, for people with advanced esophageal or gastroesophageal junction cancer that has spread. The trial is for patients whose cancer has continued to grow despite receiving at least one prior standard treatment. Researchers will monitor how patients tolerate the combination and whether it helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC ESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor University Medical Center, Charles A Sammons Cancer Center
Dallas, Texas, 75246, United States
Conditions
Explore the condition pages connected to this study.